AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06190197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics postoperatively.
Description: Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
Study NCT04772729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin faster aspart (Fiasp, Novo Nordisk)
Description: Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent.
Study NCT04772729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin faster aspart (Fiasp, Novo Nordisk)
Description: Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent.
Study NCT06280482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Description: Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
Study NCT05334186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Reasoning Training
Description: The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
Study NCT04730843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES102
Description: ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
Study NCT04817111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MIB-626
Description: Two (2) 500 mg Tablets, By Mouth, Daily
Study NCT04986397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Therapy
Description: A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
Study NCT04986397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard post-operative analgesia without the use of cryotherapy.
Study NCT04986397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard post-operative analgesia without the use of cryotherapy.
Study NCT05590286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Tablets
Description: Vonoprazan 20 mg, tablets, orally，QD
Study NCT05590286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Capsules
Description: Amoxicillin 750mg, Capsules ,orally，QID
Study NCT05590286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Capsules
Description: Amoxicillin 750mg, Capsules ,orally，QID
Study NCT05590286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 20mg, Capsules ,orally，BID
Study NCT06355778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.
Study NCT06162299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS-HBV-002
Description: YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
Study NCT04961788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemox combimed PD1 antibody
Description: 1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses.
Study NCT06330038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be used for the induction and maintenance of general anesthesia.
Study NCT06330038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled anesthetics
Description: Inhaled anesthetics will be used for the maintenance of general anesthesia.
Study NCT04800536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapidly declining plasma glucose
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
Study NCT04800536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slowly declining plasma glucose
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
Study NCT05219188 — intervention group
Intervention type: RADIATION
Intervention: 3.7 mS, CT radiation
Description: Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS
Study NCT04713865 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: The bare metal stent covers the deep femoral artery lower than 50%
Study NCT04713865 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: The bare metal stent covers the deep femoral artery in 50-90%
Study NCT04713865 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: The bare metal stent totally covers the deep femoral artery
Study NCT06129266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral care with breastmilk
Description: No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ultrasound-guided the erector spinae plane block with 0.375% ropivacaine, 0.4 mL per KG, up to 40 mL (maximum dose).
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham block
Description: Ultrasound-guided the erector spinae plane block with 0.9% saline, 0.4 mL per KG, up to 40 mL (maximum dose).
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl.
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl.
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General anesthesia
Description: Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl.
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia
Description: All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Description: All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
Study NCT04726878 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Patient-controlled analgesia
Description: All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
Study NCT04726878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
Study NCT04726878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
Study NCT04726878 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxycodone
Description: Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
Study NCT04726878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol
Description: intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study NCT04726878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study NCT04726878 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: paracetamol
Description: intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study NCT05416853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Description: CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
Study NCT05613218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Patients will have nasal cannula or oxygen mask placed as the usual standard of care.~Patients will be screened and randomized in the emergency department to either liberal or restrictive oxygenation after providing informed written consent and oxygen is titrated to the prespecified target range using an automated feedback device (O2MATIC). Consented patients will be randomly allocated to study groups via the web-based system within REDCap. The allocation will be concealed. Time at randomization will be considered as study time zero (T0). All patients will receive usual standard of care except for their O2 management. The intervention will last for 24 h. After 24 h, patients will be switched over to usual care for oxygen therapy. If the treating physician thinks, that the patient need another oxygenation target and it is thought to be harmful to continue with the allocated target, the intervention-phase can be stopped prematurely.
Study NCT06118788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG1805
Description: A single infusion of BG1805 Injection administered intravenously.
Study NCT04643652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise Reduction Bundle
Description: Implementation of a bundle of noise reducing interventions. This concerns among other things:~reduction of alarms, phone calls/pagers/ beepers, introduction of a defined period in which there is a reduction of controllable sound (quiet time), etc
Study NCT05523778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of pancreatic duct stents before enucleation surgery
Description: Advance placement of pancreatic stents endoscopically
Study NCT05523778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct enucleation surgery
Description: Patients will receive direct enucleation surgery
Study NCT05549752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide Injectable Solution
Description: Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.
Study NCT05549752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Injectable Solution
Description: Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.
Study NCT05250388 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic Bankart repair
Description: Arthroscopic Bankart repair is a minimally invasive surgical procedure with the aim to reattach and tighten the detached labrum and ligaments within the shoulder joint.
Study NCT04794712 — intervention group
Intervention type: DEVICE
Intervention: Venous reflux tools (Ultrasound and Photo plethysmography (PPG))
Description: Venous reflux tools Pain assessment tools
Study NCT04199130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is a web-based brain-training program. The investigators will assign participants to attention specific modules that they will complete at home with the goal of restoring attentional functions lost through injury via repetitive tasks of graded difficulty.
Study NCT04199130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: This is a manualized, interactive, metacognitive-strategy training designed to promote a mindful approach to complex real-life tasks and reduce lapses in attention via implementation of compensatory mechanisms for monitoring tasks.
Study NCT05480111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia at incision site
Description: 20 ml of 0.25% Bupivacaine will be given at incision site
Study NCT05480111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham QL
Description: 20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
Study NCT05480111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Local
Description: 20 mls of normal saline given at incision site
Study NCT05480111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL
Description: QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
Study NCT05478525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-200
Description: 0.5 g GLY-200 (1 x 0.5 g capsule) BID for 14 days (n=12)
Study NCT05478525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-200
Description: 1.0 g GLY-200 (2 x 0.5 g capsules) BID for 14 days (n=12)
Study NCT05478525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-200
Description: 2.0 g GLY-200 (4 x 0.5 g capsules) BID for 14 days (n=12)
Study NCT05478525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule BID for 14 days (n=4)
Study NCT05478525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules BID for 14 days (n=4)
Study NCT05478525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo capsules BID for 14 days (n=4)
Study NCT04930341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Acupressure
Description: Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
Study NCT04986436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10360
Description: Single or multiple dose(s) of HS-10360
Study NCT04986436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple dose(s) of Placebo
Study NCT05433285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Protein Subunit Recombinant Vaccine
Description: SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
Study NCT05433285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
Study NCT05008900 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy
Description: Standard of care salvage radiotherapy to the prostate bed which may include the lymph nodes.
Study NCT05143372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrolung
Description: Vibroacoustic respiratory therapy
Study NCT05466370 — intervention group
Intervention type: BIOLOGICAL
Intervention: Transfusion of Allogeneic Blood
Description: Transfusion of Allogeneic Blood
Study NCT04966663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Antineoplastic agent
Study NCT04966663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Antineoplastic agent
Study NCT04966663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antineoplastic agent
Study NCT04966663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Antineoplastic agent
Study NCT04966663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Antineoplastic agent
Study NCT04966663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ctDNA blood test
Description: Blood will be collected for ctDNA testing
Study NCT04966663 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ctDNA blood test
Description: Blood will be collected for ctDNA testing
Study NCT05710445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: Mixed reality smart glasses will be used to view a virtual monitor which mirrors the ultrasound screen in real-time.
Study NCT05555420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SRP+Laser
Description: Non-surgical periodontal therapy in combination with Laser
Study NCT05555420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRP+Laser
Description: Non-surgical periodontal therapy in combination with Laser
Study NCT06109961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen Gas for Inhalation
Description: The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
Study NCT06109961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: The accepted standard of care for perianal Crohn's disease (PCD) involves conventional therapies such as immunosuppressive agents and biologics, which can be used to induce and maintain fistula remission.
Study NCT05842161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QUIT-AD
Description: An adapted, six-session cognitive behavioral therapy intervention for smoking cessation and treatment adherence